May 1st 2024
Adalimumab-adbm is now approved for use in various indications, including psoriasis, psoriatic arthritis, and hidradenitis suppurativa.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
New Year, New drugs for Psoriasis
February 9th 2021According to one expert, recently completed phase 3 trials of novel drugs have shown impressive results, with 2021 expected to be an exciting year that will bring further advances in treatment options for patients with moderate-to-severe plaque psoriasis.
Expanding Line of Therapeutic Agents for Psoriasis
January 8th 2021Several systemic therapies are available for the treatment of patients with moderate to severe psoriasis. Continued research has further elucidated the immunopathogenesis of the disease, leading to the development of novel biologic agents that are proving to more effectively and safely address moderate to severe psoriatic lesions.
JAKs may predict psoriasis risk
November 27th 2020Genetic polymorphisms may increase psoriasis susceptibility, according to a study that found patients who have the G allele in the JAK1 gene have twice the risk of developing psoriasis, and for those with the JAK3 allele, the risk rises nearly 2-fold.
Skin of color patients lacking in psoriasis trials
November 3rd 2020A majority of psoriasis patients in phase 3 clinical trials for biologics are white, says authors of a recent study. As ethnicity and race may play a role in response to biologics, researchers emphasize need for more diversity in clinical trials.
AAD, NPF guidelines urge liver disease monitoring in psoriasis patients
September 25th 2020The latest guidelines for psoriasis from the American Academy of Dermatology and the National Psoriasis Foundation recommend physicians monitor their patients for liver disease when prescribed medication for psoriasis, such as methotrexate.
FDA, EMA accepts marketing applications for bimekizumab in psoriasis
September 22nd 2020UCB announces the U.S. Food and Drug Administration and the European Medicines Agency have accepted the Biologics License Application and Marketing Authorization Application for bimekizumab for the treatment of moderate-to-severe plaque psoriasis in adults.
Skin of color patients lacking in phase 3 psoriasis trials
September 17th 2020An overwhelming majority of subjects in phase 3 psoriasis clinical trials are Caucasian, leaving unanswered questions about how one’s ethnicity or race might impact the safety and efficacy of today’s psoriasis treatments, according to a research letter published August 7 in the British Journal of Dermatology.
Labeling improves patient understanding of psoriasis topical regimens
September 16th 2020Color-coded and picture labeling on topical psoriasis medications improved psoriasis patients’ knowledge and understanding of how to correctly use the medications, according to a study published April 10 in the Journal of Pharmacy and BioAllied Sciences.
MC2 Therapeutics collaborates EPI Health on newly approved psoriasis topical
September 2nd 2020MC2 Therapeutics and EPI Health announce they have entered into a collaboration agreement for the commercialization of calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064% (Wynzora Cream), a newly U.S. FDA-approved topical treatment for plaque psoriasis in adults.
Therapeutic, management considerations with biologics
July 24th 2020Studies offer further insight into risks associated with biologic therapy. One study suggests it’s not necessary to stop biologic therapy preoperatively to limit post-operative infections. Another systematic review does not rule out melanoma risk.